Glucosamine + Chondroitin Sulfate

Verify with FDA CVM →

16 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
16
Total Reports
1
Deaths Reported
620.0%
Death Rate

Active Ingredients

Glucosamine + Chondroitin Sulfate

Administration Routes

UnknownOral

Species Affected

Dog 16

Most Affected Breeds

Beagle 3
Retriever - Golden 2
Crossbred Canine/dog 2
Retriever - Labrador 1
Shepherd Dog - German 1
Dog (unknown) 1
Dogue de Bordeaux 1
Catahoula Leopard Dog 1
Chihuahua 1
Pit Bull 1

Most Reported Reactions

Vomiting 3
Twitching 3
Bloody diarrhoea 2
Urinary incontinence 2
Hind limb paresis 2
Ataxia 2
Not eating 2
Weakness 1
Head tilt - neurological disorder 1
Circling - neurological disorder (see also 'Behavioural disorders') 1
Leucopenia NOS 1
Elevated cholesterol (total) 1

Outcome Breakdown

Outcome Unknown
9 (56.3%)
Recovered/Normal
3 (18.8%)
Ongoing
3 (18.8%)
Euthanized
1 (6.3%)

Data Summary

Metric Value
Total adverse event reports 16
Reports involving death 1
Case-fatality rate (reported events) 620.0%
Distinct species in reports 1
Distinct breeds in reports 12
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Glucosamine + Chondroitin Sulfate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 16 adverse event reports referencing Glucosamine + Chondroitin Sulfate, including 1 reports in which the animal died — a 620.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Glucosamine + Chondroitin Sulfate. Reported administration routes include Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Glucosamine + Chondroitin Sulfate reports are Dog (16 reports), with Dog accounting for the largest share. Within those species, Beagle (3), Retriever - Golden (2), Crossbred Canine/dog (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Glucosamine + Chondroitin Sulfate are Vomiting (3), Twitching (3), Bloody diarrhoea (2), Urinary incontinence (2). Of the 16 reports with a coded outcome, Outcome Unknown is the leading category at 56.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Glucosamine + Chondroitin Sulfate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial